ReviewThe journal of headache and pain2011
Why pharmacokinetic differences among oral triptans have little clinical importance: a comment.
Review in The journal of headache and pain, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Gender bias in clinical trials of biological agents for migraine: A systematic review.PloS one · 2023Pooled it
- Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review.Advances in therapy · 2020Pooled it
- Trial
- Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.Drug design, development and therapy · 2014Trial
- Unveiling the sumatriptan dose-relief relationship.European journal of clinical pharmacology · 2026Article
- Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond.The journal of headache and pain · 2026Review
- Regional distribution of unbound eletriptan and sumatriptan in the CNS and PNS in rats: implications for a potential central action.The journal of headache and pain · 2024Article
- Nasal spray (Zavegepant) for migraines: a mini-review.Annals of medicine and surgery (2012) · 2023Article
- Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action.Journal of aerosol medicine and pulmonary drug delivery · 2022Review
- European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure.The journal of headache and pain · 2022Review
- Early alterations of cortical thickness and gyrification in migraine without aura: a retrospective MRI study in pediatric patients.The journal of headache and pain · 2021Article
- Gender-related differences in migraine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Review
- Sex-Specific Pharmacotherapy for Migraine: A Narrative Review.Frontiers in neuroscience · 2020Review
- Emerging Novel Pharmacological Non-opioid Therapies in Headache Management: a Comprehensive Review.Current pain and headache reports · 2019Review
- Female versus male migraine: an event-related potential study of visual neurocognitive processing.The journal of headache and pain · 2019Article
- Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study.European journal of clinical pharmacology · 2016Article
- Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology.Frontiers in immunology · 2016Review
- Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications.Cephalalgia : an international journal of headache · 2013Review
- Her versus his migraine: multiple sex differences in brain function and structure.Brain : a journal of neurology · 2012Article
- Dispute settlement understanding on the use of Botox in chronic migraine.The journal of headache and pain · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triptans, selective 5-HT1B/1D receptor agonists, are specific drugs for the acute treatment of migraine that have the same mechanism of action. Here, it is discussed why the differences among kinetic parameters of oral triptans have proved not to be very important in clinical practice. There are three main reasons: (1) the differences among the kinetic parameters of oral triptans are smaller than what appears from their average values; (2) there is a large inter-subject, gender-dependent, and intra-subject (outside/during the attack) variability of kinetic parameters related to the rate and extent of absorption, i.e., those which are considered as critical for the response; (3) no dose-concentration-response curves have been defined and it is, therefore, impossible both to compare the kinetics of triptans, and to verify the objective importance of kinetic differences; (4) the importance of kinetic differences is outweighed by non-kinetic factors of variability of response to triptans. If no oral formulations are found that can allow more predictable pharmacokinetics, the same problems will probably also arise with new classes of drugs for the acute treatment of migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.